The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1652
June 13, 2022
View Complete Issue         Table of Contents 2019 
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
June 13, 2022 (Issue: 1652)
The FDA has approved tenapanor (Ibsrela - Ardelyx), a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for twice-daily oral treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Tenapanor is the first NHE3 inhibitor to become...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
Article code: 1652b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.